Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.48 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183286 | 0.80 | AHR (0.61) | AHRATMCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL5579211 | 0.79 | AHR (0.68) | AHRCYP1A2CYP1A1CYP1B1CYP3A4 | |
| SCHEMBL30307539 | 0.79 | AHR (0.68) | AHRCYP1A2CYP1A1CYP1B1CYP3A4 | |
| SCHEMBL31303695 | 0.77 | CYP3A4 (0.67) | AHRATMCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL9138573 | 0.77 | CYP3A4 (0.67) | AHRATMCYP1A2CYP1A1CYP1B1 | |
| SCHEMBL1645772 | 0.77 | AR (0.54) | ATMCYP1A2CYP1A1CYP1B1MAPT | |
| Hydrochloric Acid SCHEMBL4181903 | 0.73 | ALDH1A1 (0.67) | AHRCYP1A2CYP1A1CYP1B1MAPT | |
| SCHEMBL25449242 | 0.73 | AR (0.73) | CYP1A2CYP1A1CYP1B1MAPTCYP3A4 | |
| SCHEMBL15676523 | 0.72 | ATM (0.79) | ATMCYP1A2CYP1A1CYP1B1MAPT | |
| SCHEMBL16921587 | 0.72 | KDM4E (0.46) | ATMCYP1A2CYP1A1CYP1B1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410109-B2 | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices | RESVERLOGIX CORP. (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | RESVERLOGIX CORP. (CA) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029987-A1 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices | VCAM1, ICAM1, TGFB1 | AHR 707/4885ATM 3451/4885CYP1A2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.